Author of

• 34852

  +

  FP07 - Pathology (ID 109)

  • Event: WCLC 2020
  • Type: Posters (Featured)
  • Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 34862

    +

    FP07.09 - Detection of Early Lung Cancer from Average-Risk Individuals and from Benign Nodule Carriers with a DNA Methylation Blood Test (ID 1845)

    00:00 - 00:00  |  Author(s): rongxi Yang
    • Abstract

    Introduction
    

    Early detection is the key to reducing the death of lung cancer. An effective blood-based method for the early diagnosis of lung cancer has not yet been developed. Meanwhile, current strategies to differentiate benign and malignant lung nodules are also in lack of accuracy. Here we describe a blood test that can detect lung cancer early from average-risk individuals and from benign lung nodule carriers through assessment of a methylation panel of 8 genes in peripheral blood DNA.

    Methods
    

    Two independent retrospective studies were carried out to investigate the most distinguishable methylation loci among 38 candidate genes in peripheral blood DNA. All the blood was donated before surgery and before any cancer related treatment. The methylation levels of each CpG sites were semi-quantitatively measured by mass spectrometry.

    Results
    

    Out of the investigated 38 genes, 15 showed significant methylation difference between 161 lung cancer case (90.1% in Stage I) and matched 200 cancer free individuals in the discovery round. In the validation study, 8 genes had distinguishable methylation levels among 615 lung cancer case (92.2% in Stage I), 145 surgery confirmed benign lung nodule carriers, and 809 matched cancer free individuals. Taken together, for the average-risk individuals, when the specificity was 90%, the panel of 8 methylation genes had sensitivities around 70% for the detection of early stage lung cancer regardless of subtypes, stage and tumor size. Moreover, with the specificity of 90%, this panel had even higher sensitivities around 90% for the distinguishing benign lung nodule carriers from lung cancer, and this sensitivity was 83% for the very small nodules ≤1cm.

    Conclusion
    

    Together, these findings reveal in a large clinical cohort that the utility of DNA methylation markers in the peripheral blood for the effective early diagnosis of lung cancer even for the very small tumors ≤1cm.